Hepatocellular Carcinoma in Hepatitis C-Associated Cirrhotic Patients Treated with Different Combinations of Direct-Acting Antiviral Agents Available in Pakistan: A Prospective Observational Study

Background: The hepatitis C virus (HCV) is a leading cause of chronic liver disease, including hepatic cirrhosis and hepatocellular cancer (HCC). Drugs that act directly on the virus, like as direct-acting antivirals (DAAs), are associated with improved long-term virologic responses reduced treatment time. Pakistani patients HCV-related receiving DAA medication were studied to see if they had an increased risk carcinoma Material Methods: We conducted prospective observational study at Isra University Hospital Hyderabad from July 2019 August 2020. Three hundred fourteen met inclusion criteria included. recorded baseline demographic characteristics, Child-Pugh class, model for end-stage disease (MELD) score, alpha-fetoprotein level, abdominal ultrasound/computed tomography (CT) scan before after treatment. Results: hundred-fourteen individuals took part in research. average age participant was 46.7 years. Twenty (sixty-nine) participants developing men, while nine (thirty-one percent) women (p=0.221). Five (17.2%) HCC diabetics, seventeen (58.6%) tobacco users (p=0.001). (69%) developed combination sofosbuvir daclatasvir. A sofosbuvir/velpatasvir led development (31%) (p=0.1). diagnosed eight under forty (27.6%), but 21 beyond (72.6%) (p=0.55). found 65.6 percent Child-Turcotte-Pugh class participants. Conclusion: DAAs have been linked higher HCC. Participants combo sofosbuvir/daclatasvir more likely develop than those who received alone. Keywords: Velpatasvir, Hepatocellular carcinoma, Sofosbuvir, Cirrhosis,